Halozyme Therapeutics HALO Royalties — Accounts receivable, net and contract assets

Other product segments

Similar metrics at other companies

CHDNOther receivables — Accounts receivable

$24M-4.0%

CHDNTrade receivables — Accounts receivable

$58M+18.1%

CHDNSimulcast and online wagering receivables — Accounts receivable

$53M+6.0%

OPKGovernment Contract Barda — Accounts Receivable Net

$1.9M-55.8%

MCRIHotel Receivables — Accounts Receivable Gross Current

$800K+12.4%

EPSNCommodity Contracts — Accounts Receivable Net Current

$498.13K+1,524%

FAQ

What is Halozyme Therapeutics's royalties — accounts receivable, net and contract assets?

Halozyme Therapeutics (HALO) reported royalties — accounts receivable, net and contract assets of $297.23M in Q2 2026.

How has Halozyme Therapeutics's royalties — accounts receivable, net and contract assets changed year-over-year?

Halozyme Therapeutics's royalties — accounts receivable, net and contract assets increased by 46.4% year-over-year, from $203.07M to $297.23M.

What does royalties — accounts receivable, net and contract assets mean?

This metric measures the outstanding balance of royalty payments earned but not yet collected from commercial partners, combined with recognized contract assets. It represents the company's claim to future cash inflows resulting from royalty-bearing sales that have already occurred. Monitoring this balance helps assess the timing of cash conversion and the efficiency of the royalty collection cycle.